Search

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

EHA and EMBL-EBI are launching CBTH

The Hague, May 2022 - The European Hematology Association (EHA) and the EMBL’s European Bioinformatics Institute (EMBL-EBI) are launching a new mentoring program, Computational Biology Training in Hematology (CBTH), this June.

Read more

EHA joins ESMO in calling for EU action on shortages of essential medicines

EHA joins ESMO in calling for EU action on shortages of essential medicines

The European Hematology Association (EHA) has endorsed and signed a collective Call to Action, prepared by the European Society for Medical Oncology (ESMO), on shortages of inexpensive, essential…

Read more

Hematology and oncology, pacemakers for EU HTA

EHA’s Martin Kaiser, right, addressing his fellow panelists. Left to right: Brian Cuffel (Bayer), Caroline Pothet (EMA), Roisin Adams (HTA CG), Bernhard Wörmann (DGHO) and Elisabeth de Vries (ESMO).

Read more

Training vital for new era of patient-centric healthcare

Christine Chomienne, president of the European Hematology Association (EHA), was speaking at the third annual conference of the European Alliance for Personalised Medicine (EAPM) – a Brussels-based organization that brings together stakeholders from academia, through research,…

Read more